A Study of ET-743 (Trabectedin) in Patients With Advanced Breast Cancer

• Status: Completed
• Trial end date: 2006-12-01

Summary

The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with advanced breast cancer.

• Phase: Phase 2

Details

• Lead Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
• Collaborator: PharmaMar
• Treatments: Antineoplastic Agents, Alkylating; BB 1101; Dexamethasone; Dexamethasone 21-phosphate; Dexamethasone acetate; Molecular Mechanisms of Pharmacological Action; Trabectedin